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Phthalate esters, ubiquitously used as plasti-
cizers in many polyvinyl chloride (PVC) 
products, have become widespread in the envi-
ronment (Peijnenburg et al. 2008). Diisononyl 
phthalate (DINP) is used in flooring, wire and 
cable, dip coating, coated fabrics, tubing, shoes, 
sealants, and artificial leather, and humans may 
be exposed to DINP by the oral, dermal, and 
inhalation routes (Kavlock et al. 2002). It has 
been expected that general population expo-
sure to DINP would not exceed levels of di-(2-
ethylhexyl)phthalate (DEHP) (Kavlock et al. 
2002), which are estimated at 3–30 µg/kg body 
weight/day (Doull et al. 1999). Plasticizers, 
including DINP, are not covalently bound 
to the plastics and can migrate into saliva and 
be swallowed (Earls et al. 2003; Kavlock et al. 
2002). Thus, children may be exposed to 
higher levels of DINP than are adults because 
infants and small children mouth toys and 
other articles containing DINP (Babich et al. 
2004; Kavlock et al. 2002).
Several epidemiologic studies have sug-
gested that exposure to phthalate esters may 
be associated with develop  ment of asthma, 
wheezing, and allergic symptoms (Bornehag 
et al. 2004; Jaakkola et al. 1999, 2004, 
2006). Bornehag et al. (2004) revealed the 
positive association between allergic asthma 
in children and phthalate esters in house dust. 
Thus, it is possible that phthalate esters in 
the environment may also be associated with 
development of the other allergic diseases 
such as atopic dermatitis (AD).
In our previous studies, DEHP enhanced 
AD-like skin lesions in atopic-prone NC/
Nga mice at hundreds-fold lower levels than 
the no observed adverse effect level (NOAEL) 
determined from histologic changes in 
the liver of rodents (Takano et al. 2006; 
Yanagisawa et al. 2008). The enhancing 
effects of DEHP paralleled the infiltration of 
eosinophils, mast cell degranulation, and the 
expression of pro  inflammatory proteins in 
inflamed skin. Furthermore, we have shown 
that DEHP enhanced differentiation of bone-
marrow–  derived dendritic cells (BMDCs) 
and promoted T-helper 2 (TH2) cell response 
in spleno  cytes from NC/Nga mice in vitro 
(Koike et al. 2009). 
The chronic health effects of DINP, 
including organ toxicity, carcinogenicity, and 
reproductive toxicity, have been reviewed in 
dietary studies (Babich et al. 2004; Kavlock 
et al. 2002). DINP, as a phthalate plasticizer 
with specific stereochemical and physico-
chemical characteristics, has also been shown 
to have an adjuvant effect on TH2-dependent 
immuno  globulin (Ig) production in mice 
(Larsen et al. 2002; Larsen and Nielsen 2008). 
However, the effects of DINP on allergic dis-
eases including AD have remained unclear.
In the present study, we investigated the 
effects of DINP on AD-like skin lesions in 
atopic-prone NC/Nga mice in vivo and on 
the immunologic responses of BMDCs and 
splenocytes in vitro.
Materials and Methods
Animals. Six-week-old SPF NC/NgaTndCrlj 
male mice were purchased from Charles River 
Japan (Osaka, Japan) and used at 7 weeks 
of age (body weight, 20–23 g) and 11–15 
weeks (body weight, 24–27 g) for in vivo 
and in vitro study, respectively. Mice were 
given sterile distilled water and a commercial 
diet (CE-2; CLEA Japan Inc., Tokyo, Japan) 
ad libitum, and were housed in an animal 
facility that was maintained at 22–26°C with 
40–69% humidity and a 12/12-hr light/dark 
cycle under conventional conditions. The pro-
cedures for all animal studies were approved 
by the Institutional Review Board of Japan’s 
National Institute for Environmental Studies. 
Animals were treated humanely and with 
regard for alleviation of suffering.
Protocol for in vivo study. Mice were 
divided into six groups and were injected 
intra  dermally on the ventral side of their 
right ears with saline or 5 µg mite extract 
[Dermatophagoides pteronyssinus (Dp); Cosmo 
Bio LSL, Tokyo, Japan] dissolved in 10 µL 
saline on study days 0, 3, 5, 8, 10, 12, 15, 
and 17 under anesthesia with 4% halo  thane 
(Takeda Pharmaceutical Company, Ltd., 
Osaka, Japan). DINP (Wako Pure Chemical 
Industries, Osaka, Japan), at a dose of 0, 0.15, 
1.5, 15, or 150 mg/kg/day dissolved in 0.1 mL 
olive oil (vehicle), was injected intra  peritoneally 
(IP) on days –5, 2, 9, and 16 from the first 
Dp treatment. Twenty-four hours after each 
Dp injection, we evaluated ear thickness and 
clinical scores as described previously (Takano 
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Ba c k g r o u n d: Diisononyl phthalate (DINP), a principal plasticizer in many polyvinyl chloride 
products, has been shown to have an adjuvant effect on immunoglobulin (Ig) production in mice. 
However, the effects of DINP on allergic diseases have not been fully elucidated.
oBjectives: In the present study we investigated the effects of DINP on atopic dermatitis (AD)-like 
skin lesions induced by Dermatophagoides pteronyssinus (Dp) in atopic-prone NC/Nga mice.
Me t h o d s : Mice were injected intradermally with Dp on their ears and were exposed to DINP (0, 
0.15, 1.5, 15, or 150 mg/kg/day) intraperitoneally. We evaluated clinical scores, ear thickening, his-
tologic findings, protein expression of cytokines/chemokines in the ear, and serum levels of Ig and 
histamine. Furthermore, we investigated the effects of DINP on bone-marrow–derived dendritic 
cells (BMDCs) or splenocytes in vitro. After exposure to DINP (0–100 µM), cells were evaluated 
for phenotype and function. 
re s u l t s: DINP aggravated AD-like skin lesions related to Dp. The aggravation was consistent with 
eosinophilic inflammation, mast cell degranulation, and thymic stromal lymphopoietin (TSLP) 
expression in the ear. DINP enhanced the expression of cell surface activation markers on BMDCs and 
their production of TARC/CCL17 (thymus- and activation-regulated chemokine) and MDC/CCL22 
(macrophage-derived chemokine), as well as their capacity to stimulate Dp-specific T-cell proliferation. 
DINP also enhanced interleukin-4 production and Dp-stimulated proliferation of splenocytes.
co n c l u s i o n s: DINP can aggravate AD-like skin lesions related to Dp. The mechanisms of the 
aggravation might be mediated, at least partly, through the TSLP-related activation of dendritic 
cells and by direct or indirect activation of the immune cells.
key w o r d s : antigen-presenting activity, atopic dermatitis, bone-marrow–derived dendritic cells, 
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et al. 2006). Twenty-four hours after the last 
injection of Dp (day 18), the animals were sac-
rificed, and histologic findings, protein levels 
of cytokines and chemokines in the ear tissue 
supernatants, and the levels of Ig and histamine 
in serum were evaluated.
Histologic evaluation. Right ears of mice 
were removed 24 hr after the last Dp injec-
tion (day 18) and were fixed in 10% neu-
tral phosphate-buffered formalin (pH 7.2) 
and embedded in paraffin. Sections (3 µm) 
were routinely stained with hematoxylin and 
eosin (H&E) or with toluidine blue (pH 4.0). 
Histologic analy  sis was performed using an 
AX80 microscope (Olympus, Tokyo, Japan). 
We measured the length of the cartilage 
and the numbers of infiltrated eosinophils 
and mast cells in each sample using a video 
micrometer (VM-30; Olympus). We also 
evaluated the degranulation of mast cells as 
non  degranulated (0%), mildly degranulated 
(0–50%), or severely degranulated (> 50%), 
as described previously (Takano et al. 2006).
Quantitation of cytokines/chemokines in 
the ear tissue. Right ears of mice were removed 
24 hr after the last injection of Dp (day 18) 
and were homogenized and centrifuged as pre-
viously described (Takano et al. 1997). Levels 
of interferon (IFN)-γ (Endogen, Cambridge, 
MA, USA), inter  leukin (IL)-4 (Amersham, 
Buckinghamshire, UK), IL-5 (Endogen), 
IL-13 (R&D Systems, Minneapolis, MN, 
USA), eotaxin (R&D Systems), eotaxin-2 
(R&D Systems), and thymic stromal lympho-
poietin (TSLP; R&D Systems) in the ear tissue 
supernatants were measured by enzyme-linked 
immuno  sorbent assay (ELISA) according to 
the manufacturers’ instructions. The detection 
limits of IFN-γ, IL-4, IL-5, IL-13, eotaxin, and 
TSLP were less than 10, 5, 5, 1.5, 3, and 2.63 
pg/mL, respectively. The detection limit of 
eotaxin-2 was not defined, and the assay range 
was 15.6–1,000 pg/mL. The total protein level 
in the ear tissue supernatants was measured by 
the Bradford method using a protein assay kit 
(Bio-Rad, Hercules, CA, USA). The values of 
cytokines/chemokines were compensated with 
the total protein and were expressed as pico-
grams per milligram of total protein.
Quantitation of Ig and histamine in serum. 
Blood was sampled by cardiac puncture 24 hr 
after the last injection of Dp (day 18) and 
serum was collected. Levels of Dp-specific IgG1 
were measured by ELISA with solid-phase 
antigen, as previously described (Sadakane 
et al. 2002). Levels of total IgE antibodies 
and histamine in serum were measured by 
OptELISA Set Mouse IgE (BD Biosciences, 
San Diego, CA, USA) and Histamine Enzyme 
Immunoassay Kit (SPI-BIO, Montigny le 
Bretonneux, France), respectively, according to 
the manufacturers’ instructions.
Cell preparation for in vitro study. For 
the in vitro study, bone marrow cells and 
splenocytes were prepared as previously 
described (Koike et al. 2009). Briefly, the mar-
row was flushed with Dulbecco’s calcium- and 
magnesium-free, phosphate-buffered saline 
(PBS; Takara Bio Inc., Shiga, Japan) and 
passed through nylon mesh; the red blood 
cells were then lysed with ammonium chlo-
ride. The spleen was pushed through a sterile 
stainless-steel wire mesh, and the red blood 
cells were similarly lysed. The cells were cen-
trifuged at 400 × g for 5 min at 20°C. After 
washing with PBS, the cells were resus-
pended in culture medium R10, consisting 
of GIBCO RPMI 1640 medium (Invitrogen, 
Grand Island, NY, USA) supplemented with 
10% heat-inactivated fetal bovine serum 
(MP Biomedicals Inc., Eschwege, Germany), 
100 U/mL penicillin and 100 µg/mL strep-
tomycin (Sigma, St. Louis, MO, USA), and 
50 µM 2-mercapto  ethanol (Invitrogen). The 
numbers of viable cells were determined by the 
trypan blue (Invitrogen) exclusion method.
Differentiation of BMDCs. Bone mar-
row cells (4 × 105/mL) were cultured in R10 
medium containing 20 ng/mL recombinant 
mouse granulocyte–macrophage colony-stim-
ulating factor (GM-CSF; Sigma) at 37°C in 
a 5% CO2/95% air atmosphere. On day 3, 
the same volume of medium was added to the 
culture, and on day 6, half the medium was 
replaced with fresh medium. On day 8, non-
adherent and loosely adherent cells were col-
lected by gentle pipetting. The differentiated 
BMDCs were centrifuged at 400 × g for 5 min 
at 20°C and resuspended in fresh medium. 
The numbers of viable cells were determined 
by the trypan blue exclusion method.
Exposure of immune cells to DINP. DINP 
was dissolved in dimethyl sulfoxide (DMSO; 
Sigma) and diluted with R10. The DINP solu-
tion was sonicated for 3 min using an ultrasonic 
disrupter (UD-201; TOMY, Tokyo, Japan). In 
the presence of GM-CSF (10 ng/mL), BMDCs 
(1 × 106/mL) were exposed to DINP (0, 0.1, 
1, 10, or 100 µM) in R10 containing 0.1% 
DMSO for 24 hr. Thereafter, their chemokine 
production, phenotypes, and antigen-
  presenting activity were evaluated. Next, sple-
nocytes (1 × 106/mL) were exposed to DINP 
(0, 0.1, 1, 10, or 100 µM) in R10 containing 
0.1% DMSO for 24 hr, and their cytokine 
production was examined. Moreover, spleno-
cytes (1 × 106/mL) were exposed to DINP (0, 
0.001, 0.01, 0.1, 1, or 10 µM) in R10 con-
taining 0.1% DMSO in the presence of Dp 
(10 µg/mL) for 72 hr. Thereafter, antigen-stim-
ulated proliferation and cytokine production 
of the cells were measured. Each experiment 
was performed using three individual cultures 
obtained from three animals, and two or three 
independent experiments were repeated.
Fluorescence-activated cell-sorting (FACS) 
analysis. For FACS analysis of BMDCs, we 
used the following mono  clonal antibodies: 
major histo    compatibility complex (MHC) 
class II I-A/I-E (2G9, rat IgG2a κ, fluorescein 
isothiocyanate conjugated; BD Biosciences, 
San Jose, CA, USA); co-stimulatory molecules 
CD80 [16-10A1, Ar Ham IgG1 κ, phyco-
erythrin (PE) conjugated; BD Biosciences] and 
CD86 (GL1, rat IgG2a κ, PE conjugated; BD 
Biosciences); and chemokine receptors CCR7 
(4B12, rat IgG2a κ, PE conjugated; Biolegend, 
San Diego, CA, USA) and CXCR4 (2B11/
CXCR4, rat IgG2b κ, PE conjugated; BD 
Biosciences). After DINP exposure, the cells 
(3–5 × 105) were resuspended in 100 µL PBS 
with 0.3% bovine serum albumin and 0.05% 
sodium azide (Wako Pure Chemical Industries) 
and were incubated with 1 µg of each antibody 
for 30 min on ice. After incubation, the cells 
were washed, and the fluorescence was meas-
ured by a FACSCalibur (BD, Franklin Lakes, 
NJ, USA). For each sample, we collected fluo-
rescence data from 10,000 cells and positive 
cells were expressed as percent of total events.
Antigen-presenting activity. We evaluated 
BMDC function by antigen-presenting activ-
ity and stimulating capacity for cytokine pro-
duction from responder T cells as previously 
described (Koike et al. 2009). Briefly, DINP-
exposed BMDCs were treated with 50 µg/mL 
mitomycin C (Kyowa Hakko Kogyo, Tokyo, 
Japan) for 20 min at 37°C. Splenocytes were 
prepared from NC/Nga mice sensitized with 
50 µg Dp and 1 mg aluminium hydroxide 
(three mice per experiment). T cells were iso-
lated from the splenocytes using a nylon fiber 
column (Wako Pure Chemical Industries). 
Thereafter, Dp-sensitized T cells (2 × 105) 
and BMDCs (5 × 103) were cocultured in the 
presence of 2 µg Dp in 200 µL R10 medium 
in 96-well flat-bottom plates. The cocultures 
were performed in triplicate at 37°C in a 
5% CO2/95% air atmosphere. After 91 hr, we 
measured T-cell proliferation as an indicator 
of antigen-presenting activity, and cytokine 
production from T cells.
Cell proliferation assay. We measured 
cell proliferation using a Cell-Proliferation 
ELISA kit (Roche Molecular Biochemicals, 
Mannheim, Germany) according to the 
manufacturer’s instructions. This technique is 
based on the incorporation of the pyrimidine 
analogue 5-bromo-2´-deoxyuridine (BrdU) 
instead of thymidine into the DNA of prolif-
erating cells. Cell proliferation was measured 
by adding BrdU to each well 20 hr before the 
measurement.
Quantitation of cytokines/chemokines in 
the culture supernatants. The levels of thy-
mus- and activation-regulated chemokine 
(TARC/CCL17; R&D Systems), macrophage-
derived chemokine (MDC/CCL22; R&D 
Systems), and IL-12p40 (Endogen) in the 
BMDC culture supernatants and the levels of 
IFN-γ (Endogen), IL-4 (Amersham), IL-10 
(Endogen), and IL-17 (R&D Systems) in the Koike et al.
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supernatants of BMDCs and T-cell co  cultures 
or splenocyte cultures were meas  ured by 
ELISA according to the manufacturers’ instruc-
tions. The detection limits of TARC/CCL17, 
MDC/CCL22, IL-12p40, IFN-γ, IL-4, IL-10, 
and IL-17 were less than 5, 1.2, 3, 10, 5, 12, 
and 5 pg/mL, respectively.
Statistical analysis. Data are presented 
as mean ± SE. The significance of variation 
among different groups was determined by 
one-way analysis of variance or Kruskal-
Wallis analysis. Differences among groups 
were analyzed using Dunnett’s or Steel mul-
tiple comparison test (Excel Statistics 2006, 
Social Survey Research Information Co., Ltd., 
Tokyo, Japan). A p-value < 0.05 is considered 
statistically significant. 
Results
Effects of DINP on AD-like skin lesions. To 
evaluate whether DINP affects AD-like skin 
lesions induced by Dp, we examined ear 
thickening and observed macroscopic fea-
tures. Intradermal injection of Dp significantly 
enhanced ear thickening compared with saline 
injection from 4 days after the first injection 
of Dp (Figure 1A; p < 0.05). IP injection with 
DINP significantly enhanced ear thickening 
compared with vehicle in the presence of intra-
dermal Dp from 6 days after the first injec-
tion of Dp (p < 0.05). However, we observed 
no dose-dependent effects of DINP. The ear 
thickening was most prominent in animals 
treated with 15 mg/kg/day DINP in the pres-
ence of intradermal Dp (p < 0.05). This result 
paralleled the clinical scores, including dry-
ness, wound severity, and edema (data not 
shown). We observed macroscopic features 
demonstrating that DINP aggravated AD-like 
skin lesions related to Dp (Figure 1B–D).
Histologic changes in the skin. To evaluate 
whether DINP affects histologic changes in 
the skin related to Dp, we examined the skin 
specimens stained with H&E (Figure 2A,C,E) 
or toluidine blue (Figure 2B,D,F). We found 
no pathologic changes in the saline plus vehicle 
group (Figure 2A,B). Intradermal injection of 
Dp induced the infiltration of eosinophils into 
the skin lesions compared with saline injection 
(Figure 2A,C,G; p < 0.05). IP injection with 
15 mg/kg/day DINP tended to aggravate the 
infiltration of eosinophils into the skin lesion 
compared with vehicle in the presence of intra-
dermal Dp (Figure 2C,E,G). In overall trend, 
these changes paralleled the severity of mast 
cell degranulation (Figure 2B,D,F,H).
Protein expression of cytokines/chemo-
kines in the skin. We investigated whether 
DINP affects the protein expression of TH1/
TH2 cytokines and chemokines in the skin 
related to Dp. Intradermal injection of Dp 
significantly increased the expression of IL-4, 
IL-5, and IL-13 and significantly decreased 
the expression of IFN-γ compared with 
saline injection [see Supplemental Material, 
Table 1 (doi:10.1289/ehp.0901255); IL-4, 
p < 0.01; IL-5, p < 0.05; IL-13, p < 0.01; 
IFN-γ, p < 0.01]. IP treatment with DINP 
did not clearly affect the expression of these 
cytokines, although DINP tended to decrease 
IFN-γ expression compared with vehicle in 
the presence of intradermal Dp. Dp injec-
tion alone increased the expression of eotaxin, 
eotaxin-2, and TSLP compared with saline 
injection (see Supplemental Material, Table 1; 
eotaxin, p < 0.01). However, DINP signifi-
cantly decreased the expression of eotaxin and 
eotaxin-2 compared with vehicle in the pres-
ence of intradermal Dp (p < 0.05). On the 
other hand, DINP at 0.15 mg/kg/day signifi-
cantly increased TSLP expression compared 
with vehicle in the presence of intradermal 
Dp (p < 0.05). The expression of IL-12p40 
was not detected (data not shown).
Effects of DINP on the levels of Ig and 
histamine in serum. To evaluate the adjuvant 
capacity of DINP for Ig production, we meas-
ured the levels of Dp-specific IgG1 and total 
IgE in serum. We also investigated whether 
DINP affects histamine release in serum 
related to Dp. Intradermal injection of Dp 
significantly increased the levels of Dp-specific 
IgG1 and total IgE and tended to increase his-
tamine levels in serum compared with saline 
injection [see Supplemental Material, Table 1 
(doi:10.1289/ehp.0901255); p < 0.01]. IP 
DINP treatment did not affect the levels of 
Dp-specific IgG1 and total IgE in serum. In 
the presence of intradermal Dp, DINP signifi-
cantly increased histamine levels in serum com-
pared with saline injection (p < 0.01), except at 
1.5 mg/kg/day. However, we found no signifi-
cant difference between DINP and vehicle in 
the presence of intra  dermal Dp.
Effects of DINP on BMDCs in vitro. To 
evaluate whether DINP affects the pheno-
types and function of BMDCs in NC/Nga 
mice, we examined the production of TH1/
TH2 cytokines and chemokines, the expres-
sion of cell surface molecules, and antigen-
presenting activity of BMDCs after exposure 
to DINP in vitro. DINP exposure for 24 hr 
significantly increased the production of TH2 
chemokines, TARC/CCL17 (Figure 3A; 
100 µM DINP, p < 0.05) and MDC/CCL22 
(Figure 3B; 100 µM DINP, p < 0.05), from 
BMDCs compared with control (0 µM 
DINP). We did not detect the TH1 cytokine 
IL-12p40 in any BMDC cultures (data not 
shown). DINP also significantly increased the 
Figure 1. Effects of DINP on AD-like skin lesions induced by Dp on mouse ears. (A) Thickness of the ears 
24 hr after each intradermal injection of Dp (mean ± SE of 12 animals per group). (B–D) Macroscopic fea-
tures of the ears from the saline + vehicle group (B), Dp + vehicle group (C), and Dp + DINP 15 mg/kg/day 
group (D) 24 hr after the last injection of Dp. 
*p < 0.05, and **p < 0.01 for Dp-treated groups compared with the saline + vehicle group. #p < 0.05 for Dp + DINP groups 
compared with the saline + vehicle group. §p < 0.05, and §§p < 0.01 for Dp + DINP 150 mg/kg/day versus Dp + vehicle. 
†p < 0.05, and ††p < 0.01 for Dp + DINP 15 mg/kg/day versus Dp + vehicle. ‡p < 0.05 for Dp + DINP 1.5 mg/kg/day versus 
Dp + vehicle. ‡‡p < 0.05 for Dp + DINP 0.15 mg/kg/day versus Dp + vehicle. 
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expression of the chemokine receptors CCR7 
(Figure 3C; 100 µM DINP, p < 0.01) and 
CXCR4 (Figure 3D; 10 or 100 µM DINP, 
p < 0.05), MHC class II (Figure 3E,F; 1 or 
10 µM DINP, p < 0.01; 0.1 or 100 µM 
DINP, p < 0.05), CD80 (Figure 3E; 100 µM 
DINP, p < 0.05), and CD86 (Figure 3F; 1, 
10, or 100 µM DINP, p < 0.01) on BMDCs 
compared with controls. After the increases, 
Dp-specific antigen-presenting activity of 
BMDCs was significantly enhanced by 
DINP compared with control (Figure 4A; 
1 or 10 µM DINP, p < 0.01; 100 µM 
DINP, p < 0.05). The levels of IL-4 in the 
cocultures of T cells and BMDCs exposed 
to DINP were also increased compared with 
controls (Figure 4B; 1 µM DINP, p < 0.05; 
10 µM DINP, p < 0.01). The levels of IFN-γ 
(Figure 4C) and IL-17 (Figure 4D) tended to 
increase in response to DINP exposure in the 
same manner as IL-4 without significance. The 
level of IL-10 was lower than the detection 
limit (data not shown).
Effects of DINP on splenocytes in vitro. To 
evaluate whether DINP affects the activation 
of splenocytes in NC/Nga mice, we exam-
ined the production of TH1/TH2 cytokines 
and Dp-stimulated proliferation of spleno-
cytes after exposure to DINP in vitro. DINP 
exposure for 24 hr significantly increased IL-4 
production from splenocytes compared with 
controls (Figure 5A; 10 µM DINP, p < 0.05; 
100 µM DINP, p < 0.01). The levels of IL-10, 
IFN-γ, and IL-12p40 were < 10 pg/mL, and 
we observed no effects of DINP (data not 
shown). On the other hand, 72-hr exposure 
to DINP in the presence of Dp significantly 
increased proliferation of splenocytes at 
0.001–1 µM and decreased the proliferation 
at 10 µM compared with controls (Figure 5B; 
0.001 or 1 µM DINP, p < 0.01; 0.01, 0.1, or 
10 µM DINP, p < 0.05).
Discussion
In the present study, we found that DINP 
aggravated AD-like skin lesions related to Dp 
in NC/Nga mice. The aggravation was con-
sistent with the degree of eosinophilic inflam-
mation, mast cell degranulation, and TSLP 
expression in the inflamed ear. DINP also 
enhanced the expression of cell surface activa-
tion markers on BMDCs; the production of 
TARC/CCL17 and MDC/CCL22; and the 
Dp-specific antigen presentation, IL-4 pro-
duction, and Dp-stimulated prolifera  tion of 
splenocytes from NC/Nga mice in vitro.
DINP is ubiquitously used in PVC prod-
ucts and, along with DEHP, is widespread in 
the environment. Although previous studies 
have shown that DINP possesses adjuvant 
activity characterized by antigen-specific IgG1 
antibody production (Larsen et al. 2002; 
Larsen and Nielsen 2008), the effects of 
DINP on allergic diseases or symptoms and 
on under  lying cellular and molecular mecha-
nisms remain unclear.
The present study showed that DINP (0.15, 
1.5, 15, or 150 mg/kg/day) caused aggrava-
tion of AD-like skin lesions related to Dp in 
NC/Nga mice, as evidenced by macroscopic 
(Figure 1) and microscopic (Figure 2) examina-
tion. We observed no dose-dependent effects of 
DINP, and the symptoms were most prominent 
on exposure to 15 mg/kg/day DINP in the 
presence of intradermal Dp (Figure 1A). This 
dose of DINP has been reported as a NOAEL 
for general chronic oral toxicity in rats (Lington 
et al. 1997). Additionally, based on oral toxi-
cologic studies on DINP in rats, the NOAEL 
for developmental toxicity and reproductive 
toxicity is 100–200 and 665–802 mg/kg/day, 
respectively (Kavlock et al. 2002). Accordingly, 
Figure 2. Effects of DINP on histologic changes in the ear 24 hr after the last intradermal injection of Dp. 
Photomicrographs of ear tissue sections from the saline + vehicle group (A, B), Dp + vehicle group (C, D), 
and Dp + DINP 15 mg/kg/day group (E, F) stained with H&E (A, C, E) or toluidine blue (B, D, F) and observed 
at 100× (A, C, E) and 400× (B, D, F, and E inset); data are representative of five animals per group. The infiltra-
tion of eosinophils (G) and the degranulation of mast cells (H) evaluated as the number of cells (mean ± SE) 
per millimeter of cartilage from five animals per group. 
*p < 0.05, and **p < 0.01 for Dp-treated groups compared with the saline + vehicle group.
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our present results indicate that DINP can 
aggravate AD-like skin lesions related to Dp at 
lower levels than those used in previous studies, 
whereas a NOAEL based on oral intake cannot 
be directly compared with an injected dose.
Compared with vehicle treatment, DINP 
exposure tended to increase hista  mine release 
in serum [see Supplemental Material, Table 1 
(doi:10.1289/ehp.0901255)] in the presence 
of intra  dermal Dp. The increases in hista-
mine may be one of the mechanisms underly-
ing the aggravation of AD-like skin lesions 
by DINP. In contrast, DINP did not clearly 
affect Ig levels or the expression of TH1/
TH2 cytokines such as IFN-γ, IL-4, IL-5, 
and IL-13. However, DINP signifi  cantly 
decreased eotaxin and eotaxin-2 expression 
in ear tissue in the presence of intradermal 
Dp, compared with vehicle (see Supplemental 
Material, Table 1), even though eosino  philic 
inflammation and mast cell degradation in 
the ear were present in parallel with the aggra-
vation of AD-like skin lesions (Figure 2). This 
result differed from that in our previous study 
on DEHP (Takano et al. 2006), in which 
we observed increased expression of eotaxin 
and macrophage inflammatory protein-1α in 
the ear. It is possible that DINP induced the 
expression of TH2 cytokines and chemok-
ines at an earlier phase and that this induc-
tion might contribute to the aggravation of 
the symptoms. A time-course study is needed 
to elucidate the correlation between symp-
toms and inflammatory mediators. In addi-
tion, it is possible that DINP may aggravate 
AD-like skin lesions through mecha  nisms dif-
ferent from those of DEHP. For instance, 
DINP enhanced TSLP expression compared 
with vehicle in the presence of intradermal 
Dp (see Supplemental Material, Table 1). 
Previous studies have shown that TSLP is 
associated with AD and asthma in humans 
(Soumelis et al. 2002; Ying et al. 2005) and 
mice (Li et al. 2005; Zhou et al. 2005). TSLP 
is an epithelial-cell–derived IL-7-like cyto-
kine that strongly activates dendritic cells. 
TSLP-activated dendritic cells produce TH2-
attracting chemokines (Soumelis et al. 2002) 
and then induce TH2 cell activation, initiating 
allergic inflammation by triggering IgE pro-
duction, eosinophilia, and mucus production 
(Liu 2006; Liu and Frederick 2009). In a pre-
liminary study, we observed that exposure to 
0.15 mg/kg/day DINP further enhanced the 
expression of activation markers of antigen-
presenting cells, including dendritic cells, and 
that these cell numbers in local lymph node 
cells compared with vehicle in the presence 
of intradermal Dp (data not shown). This 
result is consistent with the enhancement of 
TSLP expression. Therefore, DINP may acti-
vate dendritic cells in Dp-related inflamma-
tory sites through the enhancement of TSLP 
production. The activated dendritic cells can 
migrate into local lymph nodes, leading to 
acceleration of antigen presentation and TH2 
cell activation.
Thus, we focused on dendritic cells and 
investigated the effects of DINP on BMDCs 
in vitro. In the present study we found that 
24-hr DINP exposure significantly increased 
the production of the TH2-attracting 
chemokines TARC/CCL17 (Figure 3A) 
and MDC/CCL22 (Figure 3B) but not the 
TH1-polarizing cytokine IL-12p40 (data not 
shown), and increased the expression of CCR7, 
CXCR4 (Figure 3C,D), MHC class II, CD80, 
and CD86 (Figure 3E,F) in BMDCs. CCR7 
and CXCR4 are chemo  kine receptors for 
regulating dendritic cell function and migra-
tion into draining lymph nodes (Kabashima 
et al. 2007). MHC class II (Niederhuber 
and Shreffler 1977) and costimulatory mol-
ecules CD80 and CD86 (Freeman et al. 1993; 
Lenschow et al. 1993) are essential for anti-
gen presentation. DINP exposure significantly 
enhanced Dp-specific antigen-  presenting 
activity of BMDCs compared with the con-
trol (Figure 4A). DINP-exposed BMDCs 
consequently stimulated IL-4 production 
in the cocultures with Dp-sensitized T cells 
(Figure 4B). The production of IFN-γ and 
IL-17 in the co  cultures was not significantly 
altered by DINP exposure (Figure 4C,D). 
DINP also enhanced BMDC differentiation 
after 6-day culture of bone marrow cells in the 
presence of DINP (data not shown). However, 
DINP more clearly affected BMDC activa-
tion instead of BMDC differentiation. In con-
trast, our previous study (Koike et al. 2009) 
showed that DEHP may predominantly affect 
BMDC differentiation rather than BMDC 
activation. The different immune stimulatory 
effects of these phthalates may be related to 
their chemi  cal structures and properties. Larsen 
and Nielsen (2008) suggested that the adjuvant 
Figure 3. Effects of DINP on the production of chemokines and the expression of cell surface molecules on 
BMDCs. Levels of TARC/CCL17 (A) and MDC/CCL22 (B) in the BMDC culture supernatant after DINP expo-
sure for 24 hr as measured by ELISA. (C,D) Expression of chemokine receptors CCR7 (C) and CXCR4 (D), 
and (E,F) expression of cell surface molecules associated with antigen presentation, MHC class II (MHC II) 
and CD80 (E) or MHC II and CD86 (F), on BMDCs after 24-hr DINP exposure as analyzed by flow cytometry. 
Data are the mean ± SE of three individual cultures from three animals and are representative of two or 
three independent experiments. 
*p < 0.05, and **p < 0.01 compared with control. 
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effects of phthalates are highly influenced by 
both stereo  chemical and physico  chemical 
properties.
Second, we investigated the effects of 
DINP on splenocytes in vitro in order to 
evaluate whether DINP affects systemic 
immune responses. Exposure to DINP for 
24 hr significantly increased IL-4 production 
from splenocytes in a concentration-depen-
dent manner (Figure 5A). The levels of IL-10, 
IFN-γ, and IL-12p40 were < 10 pg/mL, and 
we observed no effects of DINP (data not 
shown). In a previous study Lee et al. (2004) 
showed that in vitro and/or in vivo exposure 
to DEHP and DINP enhances IL-4 produc-
tion in CD4+ T cells and activation of IL-4 
gene promoter containing binding sites for 
the NFAT (nuclear factor of activated T cells) 
transcription factor. That study and our pres-
ent findings suggest that DEHP and DINP 
may enhance allergic responses by enhanc-
ing IL-4 production in CD4+ T cells via an 
NFAT-dependent pathway. Further studies 
are needed to identify the signaling pathways, 
including transcriptional factors, associated 
with the effects of DEHP and DINP on 
T cells. Moreover, exposure to DINP at low 
concentrations (0.001–1 µM) for 72 hr sig-
nificantly increased Dp-stimulated splenocyte 
proliferation (Figure 5B). The DINP-induced 
increase showed maximal activity at these con-
centrations and then decreased. We previously 
showed a similar effect with DEHP (Koike 
et al. 2009). Therefore, these results suggest 
that prolonged exposure of splenocytes to low 
concentrations of phthalates such as DEHP 
and DINP can activate their proliferation in 
the presence of antigen.
Conclusions
DINP can aggravate AD-like skin lesions 
related to Dp in NC/Nga mice at the same 
levels as the NOAEL for general toxicity. 
TSLP, in particular, may play a crucial role 
in this aggravation. Furthermore, DINP can 
enhance TH2 responses through the activa-
tion of BMDCs and splenocytes in vitro. The 
mechanisms underlying the aggravation of 
AD-like skin lesions by DINP may be linked, 
in part, to the enhanced TSLP-mediated acti-
vation of dendritic cells and a direct or indirect 
activation of the immune cells.
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